BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 35927489)

  • 1. Molecular map of chronic lymphocytic leukemia and its impact on outcome.
    Knisbacher BA; Lin Z; Hahn CK; Nadeu F; Duran-Ferrer M; Stevenson KE; Tausch E; Delgado J; Barbera-Mourelle A; Taylor-Weiner A; Bousquets-Muñoz P; Diaz-Navarro A; Dunford A; Anand S; Kretzmer H; Gutierrez-Abril J; López-Tamargo S; Fernandes SM; Sun C; Sivina M; Rassenti LZ; Schneider C; Li S; Parida L; Meissner A; Aguet F; Burger JA; Wiestner A; Kipps TJ; Brown JR; Hallek M; Stewart C; Neuberg DS; Martín-Subero JI; Puente XS; Stilgenbauer S; Wu CJ; Campo E; Getz G
    Nat Genet; 2022 Nov; 54(11):1664-1674. PubMed ID: 35927489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
    Abramenko I; Bilous N; Chumak A; Kryachok I; Fedorenko Z; Martina Z; Dyagil I
    Leuk Res; 2021 Nov; 110():106686. PubMed ID: 34492598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The
    Perez-Chacon G; Zapata JM
    Front Immunol; 2021; 12():627602. PubMed ID: 33912159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of immunoglobulin gene somatic high mutation on prognosis of the chronic lymphocytic leukemia].
    Liu H; Zhu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1588-91. PubMed ID: 20030953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV
    Burns A; Alsolami R; Becq J; Stamatopoulos B; Timbs A; Bruce D; Robbe P; Vavoulis D; Clifford R; Cabes M; Dreau H; Taylor J; Knight SJL; Mansson R; Bentley D; Beekman R; Martín-Subero JI; Campo E; Houlston RS; Ridout KE; Schuh A
    Leukemia; 2018 Feb; 32(2):332-342. PubMed ID: 28584254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
    Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
    Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
    Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
    Raponi S; Ilari C; Della Starza I; Cappelli LV; Cafforio L; Piciocchi A; Arena V; Mariglia P; Mauro FR; Gentile M; Cutrona G; Moia R; Favini C; Morabito F; Rossi D; Gaidano G; Guarini A; Del Giudice I; Foà R
    Br J Haematol; 2020 Jun; 189(5):853-859. PubMed ID: 32064595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cells.
    Ghiotto F; Marcatili P; Tenca C; Calevo MG; Yan XJ; Albesiano E; Bagnara D; Colombo M; Cutrona G; Chu CC; Morabito F; Bruno S; Ferrarini M; Tramontano A; Fais F; Chiorazzi N
    Mol Med; 2011; 17(11-12):1188-95. PubMed ID: 21785810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics and epigenetics of CLL.
    Paul P; Stüssi G; Bruscaggin A; Rossi D
    Leuk Lymphoma; 2023 Mar; 64(3):551-563. PubMed ID: 36503384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.
    Kotaskova J; Tichy B; Trbusek M; Francova HS; Kabathova J; Malcikova J; Doubek M; Brychtova Y; Mayer J; Pospisilova S
    J Mol Diagn; 2010 May; 12(3):328-34. PubMed ID: 20228263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.
    Delgado J; Salaverria I; Baumann T; Martínez-Trillos A; Lee E; Jiménez L; Navarro A; Royo C; Santacruz R; López C; Payer AR; Colado E; González M; Armengol L; Colomer D; Pinyol M; Villamor N; Aymerich M; Carrió A; Costa D; Clot G; Giné E; López-Guillermo A; Campo E; Beà S
    Haematologica; 2014 Nov; 99(11):e231-4. PubMed ID: 24997154
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
    Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.
    Eagle GL; Zhuang J; Jenkins RE; Till KJ; Jithesh PV; Lin K; Johnson GG; Oates M; Park K; Kitteringham NR; Pettitt AR
    Mol Cell Proteomics; 2015 Apr; 14(4):933-45. PubMed ID: 25645933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.
    Tobin G; Rosenquist R
    Med Oncol; 2005; 22(3):217-28. PubMed ID: 16110132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia.
    Stanganelli C; Travella A; Bezares R; Slavutsky I
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):447-457.e2. PubMed ID: 23665144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
    Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
    Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of extensive mutations in the VH5 genes used in common B cell chronic lymphocytic leukemia.
    Rassenti LZ; Kipps TJ
    J Exp Med; 1993 Apr; 177(4):1039-46. PubMed ID: 7681468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.